Suchergebnisse - "Cook, Gordon"

PubPharm (7)

1

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

enthalten in: Blood | 2022

von San-Miguel, J. | Avet-Loiseau, H. | Paiva, B. | +24

CommentIn: Blood. 2022 Jan 27;139(4):469-471. - PMID 35084473

2

Health-related quality of life in patients with relapsed or refractory multiple myeloma : treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

enthalten in: British journal of haematology | 2021

von Plesner, T. | Dimopoulos, M. | Oriol, A. | +15

3

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX

enthalten in: Blood cancer journal | 2020

von Kaufman, J. | Dimopoulos, M. | White, D. | +26

4

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : extended follow-up of POLLUX, a randomized, open-label, phase 3 study

enthalten in: Leukemia | 2020

von Bahlis, N. | Dimopoulos, M. | White, D. | +16

5

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age : subgroup analysis of the phase 3 CASTOR and POLLUX studies

enthalten in: Haematologica | 2020

von Mateos, M. | Spencer, A. | Nooka, A. | +16

6

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma : updated analysis of POLLUX

enthalten in: Haematologica | 2018

von Dimopoulos, M. | San-Miguel, J. | Belch, A. | +30

7

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2016

von Dimopoulos, M. | Oriol, A. | Nahi, H. | +122

CommentIn: N Engl J Med. 2016 Oct 6;375(14 ):1390-1392. - PMID 27705251

1
[1]